Clinical trial NCT01773018: Phase I Study of the Volitinib (HMPL-504) in Patients With Advanced Solid Tumors
Official title: A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of HMPL-504 in Patients With Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Tumor
Lead sponsor: Hutchmed
Sponsor class: INDUSTRY
Collaborators: name: Sir Charles Gairdner Hospital
name: Austin Hospital, Melbourne Australia
name: Monash University
First posted: 2013-01-21
Enrollment: 47
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Volitinib (HMPL-504) is a novel, highly potent and selective small molecule inhibitor of c-Met kinase. In preclinical studies, it demonstrated strong in vitro and in vivo activity against c-Met kinase and its downstream signaling targets and inhibited tumor cell growth. This first-in-human study is conducted to assess the maximum tolerated dose (MTD) and dose-limiting toxicity (DLT), to evaluate the pharmacokinetics, safety and preliminary anti-tumor activity of HMPL-504 at single doses and multiple doses.

Detailed description: This is a Phase I, first-in-human, open-label, dose-escalation study of Volitinib (HMPL-504) administered orally once every day(QD) to patients with locally advanced or metastatic solid tumors.There are two stages to this study : a dose-escalation stage and a dose-expansion stage. The dose-escalation stage is designed to evaluate the safety, tolerability, and pharmacokinetics of single dose and repeat doses of HMPL-504 given once every day (QD). An alternative dosing schedule of twice every day (BID) may be investigated if pharmacokinetic studies indicate faster than anticipated clearance of HMPL-504.

All patients will be carefully followed for adverse events during the study treatment and for 30 days after the last dose of study drug. Subjects of this study will be permitted to continue therapy with only safety monitoring and bimonthly assessments for progression, if the product is well tolerated and the subject has stable disease or better.

Eligibility criteria: Inclusion Criteria:

* Signed Informed Consent Form
* Age≥18 years
* Histologically or cytologically documented, incurable, locally advanced, or metastatic solid malignancy that has progressed on, or failed to respond to, at least one prior systemic therapy
* Evaluable or measurable disease per Response Evaluation Criteria in Solid Tumors(RECIST)
* Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1
* Male or female patients of child-producing potential must agree to use double barrier contraception, condoms, sponge, foams, jellies, diaphragm or intrauterine device (IUD), contraceptives (oral or parenteral), Implanon, injectables or other avoidance of pregnancy measures during the study and for 90 days after the last day of treatment
* In the dose expansion stage, the patient's informed consent to providing fresh biopsy tumor sample at baseline and day 7 should be obtained. Patients with gastric cancer , NSCLC, colorectal cancer, breast cancer and hepatocellular carcinoma(HCC) are preferred to be enrolled into the dose expansion cohort.

Exclusion Criteria:

• Inadequate hematologic and organ function, defined by the following (hematologic parameters must be assessed ≥14 days after a prior treatment, if any):

* Absolute neutrophil count \<1500 cells/L
* Hemoglobin \<9 g/dL
* Total bilirubin \>1.5 × the upper limit of normal （ULN） with the following exception: Patients with known Gilbert disease who have

serum bilirubin level ≤3× the upper limit of normal（ULN） and normal AST/ALT may be enrolled.

* Aspartate aminotransferase （AST） and/or Alanine transaminase（ALT） \>2.5 × the upper limit of normal（ULN） with the following exception: Patients with documented liver metastases may have AST and/or ALT levels ≤5 ×the upper limit of normal（ULN）.
* Serum creatinine \>1.5 × the upper limit of normal (ULN) with the following exception: A creatinine clearance of ≥50 mL/min based on a documented 24-hour urine collection.
* International normalized ratio (INR)\>1.5× the ULN or activated partial thromboplastin time (aPTT)\>1.5×the ULN
* The INR applies only to patients who do not receive therapeutic anti-coagulation.

  • Any anti-cancer therapy, including chemotherapy, hormonal therapy, biologic therapy, radiotherapy, or herbal therapy within 4 weeks prior to initiation of study treatment with the following exceptions:
* Hormonal therapy with gonadotropin-releasing hormone (GnRH) agonists for prostate cancer
* Hormone-replacement therapy or oral contraceptives
* Palliative radiation to bone metastases \> 2 weeks prior to Day 1
* Herbal therapy \>1 week prior to Day 1

  * Adverse events from prior anti-cancer therapy that have not resolved to Grade ≤ 1, except for alopecia
  * Clinical significant active infection
  * Known clinically significant history of liver disease, including viral or other hepatitis, current alcohol abuse, or cirrhosis
  * Known human immunodeficiency virus infection
  * Pregnant (positive pregnancy test) or lactating women
  * New York Heart Association (NYHA) Class II or greater congestive heart failure
  * History of myocardial infarction or unstable angina within 6 months prior to Day 1
  * History of stroke or transient ischemic attack within 6 months prior to Day 1
  * Active or untreated brain metastasis
  * Inability to take oral medication, prior surgical procedures affecting absorption, or active peptic ulcer disease
  * Inability to comply with study and follow-up procedures
  * Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding that, in the investigator's opinion, gives reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that may affect the interpretation of the results or renders the patient at high risk from treatment complications.

Primary outcomes:
measure: The safety and tolerability of single and multiple doses of HMPL-504 administered to patients.
timeFrame: up to 20 months
Secondary outcomes:
measure: Pharmacokinetic Assessments for area under curve (AUC), Cmax and Tmax .
timeFrame: Day 1-3 Single Dose and Day 1-21 Steady State
Other outcomes:
measure: Objective Response Rate （ORR)
timeFrame: participants will be followed for the duration of hospital stay,an expected average of 3 months.
Locations:
city: Nedlands
country: Australia
facility: Sir Charles Gairdner Hospital
state: Western Australia
city: Clayton
country: Australia
facility: Southern Health and Monash Institute of Medical Research
city: Melbourne
country: Australia
facility: Austin Health
Study officials:
affiliation: Sir Charles Gairdner Hospital & University of WA
name: Michael Millward, MD,Ph.D
role: PRINCIPAL_INVESTIGATOR
affiliation: Austin Hospital, Melbourne Australia
name: Hui Gan, MD,Ph.D
role: PRINCIPAL_INVESTIGATOR
affiliation: Southern Health and Monash Institute of Medical Research
name: Jason Lickliter, MD,Ph.D
role: PRINCIPAL_INVESTIGATOR
References: